

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
-----MATERIAL NAME: Neo-Synephrine Hydrochloride
List Number: 1793, 1800MANUFACTURER: Hospital Products Division
Abbott Laboratories
Abbott Park, Illinois 60064EMERGENCY TELEPHONE NUMBER: 1-847-937-7970
CHEMTREC TELEPHONE NUMBER: 1-800-424-93002. COMPOSITION/INFORMATION ON INGREDIENTS
-----INGREDIENT NAME: Phenylephrine Hydrochloride *
CAS/RTECS NUMBERS: 61-76-7 / DO7525000
OSHA-PEL 8HR TWA: N/L
STEL: N/L
CEILING: N/L
ACGIH-TLV 8HR TWA: N/L
STEL: N/L
CEILING: N/L
OTHER 8HR TWA: N/A
LIMITS STEL: N/A
CEILING: N/A

* Hazardous per OSHA criteria

3. HAZARDS INFORMATION

EMERGENCY OVERVIEW: In clinical use, this material constricts blood vessels and increases blood pressure. The active ingredient is a sympathomimetic amine, is a potent drug and is toxic by ingestion. Target organs include the cardiovascular system and the eyes.

ROUTE(S) OF ENTRY: Skin: Unlikely
Inhalation: Unlikely
Ingestion: Unlikely

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

3. HAZARDS INFORMATION, continued

INGESTION RATING: Possibly toxic

SKIN ABSORPTION RATING: N/D

INHALATION RATING: N/D

CORROSIVENESS RATING: N/D

SKIN CONTACT RATING: N/D.

SKIN SENSITIZATION RATING: N/D.

EYE CONTACT RATING: N/D.

TARGET ORGANS: Cardiovascular system, eyes.

CARCINOGENICITY RATING: NTP: N/L IARC: N/L OSHA: N/L

ACGIH: N/L

None

SIGNS AND SYMPTOMS: N/D. In clinical use, side effects can include headache, slowed heart rate, excitability and restlessness. Overdosage may induce ventricular extrasystoles, short paroxysms of ventricular tachycardia, sensation of fullness in the head and tingling of the extremities. Inadvertent application to the eyes could result in mydriasis and decreased intraocular pressure while chronic nasal use could result in chronic swelling and rhinitis. Ocular or nasal use can result in systemic effects.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Hypersensitivity to phenylephrine. Pre-existing severe hypertension or ventricular tachycardia. Concurrent use of oxytocic drugs. Hypothyroidism. Cardiovascular disease. Use of monoamine oxidase inhibitors.

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

4. FIRST AID MEASURES

EYES: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Phentolamine should relieve excessive elevation of blood pressure. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

SKIN: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Phentolamine should relieve excessive elevation of blood pressure. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

INGESTION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Phentolamine should relieve excessive elevation of blood pressure. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

INHALATION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Phentolamine should relieve excessive elevation of blood pressure. Provide symptomatic/supportive care, monitoring cardiovascular function, as necessary.

5. FIRE FIGHTING PROCEDURES

FLASH POINT: Non-flammable

FLASH POINT METHOD: N/A

LOWER EXPLOSIVE LIMIT(%): N/D

UPPER EXPLOSIVE LIMIT(%): N/D

AUTOIGNITION TEMPERATURE: N/A

FIRE & EXPLOSION HAZARDS: N/D

EXTINGUISHING MEDIA: Use media appropriate for primary cause of fire.

FIRE FIGHTING INSTRUCTIONS: Fire fighters should wear self-contained breathing apparatus, flame and chemical resistant boots and gloves.

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

6. ACCIDENTAL RELEASE MEASURES

SPILL OR RELEASE PROCEDURES: Absorb with suitable material and place into container for disposal in accordance with Section 13.

7. HANDLING AND STORAGE

HANDLING: Protect from light.

STORAGE: Store at room temperature up to 30 deg. C (86 deg. F)

SPECIAL PRECAUTIONS: Protect from light. Retain in carton until time of use.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ENGINEERING CONTROLS: No special provisions are required.

RESPIRATORY PROTECTION: Not needed during normal product use.

SKIN PROTECTION: If skin contact is likely, impervious gloves are recommended.

EYE PROTECTION: Not required during typical product use.

OTHER PROTECTION: N/D

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: Clear, colorless solution.

ODOR: N/D

BOILING POINT: Water (approx.)

MELTING/FREEZING POINT: Water (approx.)

VAPOR PRESSURE (mm Hg): N/D

VAPOR DENSITY (Air=1): N/D

EVAPORATION RATE: N/D

BULK DENSITY: 1.006 - 1.008

SPECIFIC GRAVITY: N/D

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

9. PHYSICAL AND CHEMICAL PROPERTIES, continued

SOLUBILITY: Freely soluble in water.

pH: 3.0 - 6.5

VISCOSITY: N/D

10. STABILITY AND REACTIVITY

CHEMICAL STABILITY: Stable.

INCOMPATIBILITIES: N/D

HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition it emits toxic fumes of HCl.

HAZARDOUS POLYMERIZATION: N/D

11. TOXICOLOGICAL INFORMATION

ORAL TOXICITY: N/D. LD50 = 120-350 mg/kg in rats for phenylephrine hydrochloride (TOXIC).

DERMAL TOXICITY: N/D

INHALATION TOXICITY: N/D

CORROSIVENESS: N/D

DERMAL IRRITATION: N/D. Other clinical formulations of phenylephrine hydrochloride applied to the nasal mucosa to relieve nasal and/or sinus congestion.

OCULAR IRRITATION: N/D. Other clinical formulations of phenylephrine hydrochloride applied to eyes to relieve congestion, itching and minor irritation.

DERMAL SENSITIZATION: N/D

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

11. TOXICOLOGICAL INFORMATION, continued

SPECIAL TARGET ORGAN EFFECTS: N/D. Phenylephrine hydrochloride is a sympathomimetic amine that constricts blood vessels, increases blood pressure and causes the pupils of the eyes to dilate. It produced increased sister-chromatid exchange in an assay in Chinese hamster ovary cells but has produced negative or equivocal results in other assays for effects on mutagenicity.

CARCINOGENICITY INFORMATION: N/D. Phenylephrine hydrochloride not carcinogenic in two-year studies in mice and rats at oral (diet) dosages up to 50 mg/kg/day and 270 mg/kg/day, respectively. Reduced incidence of mononuclear cell leukemia and pheochromocytoma found in male rats.

12. ECOLOGICAL INFORMATION

ECOLOGICAL INFORMATION: N/D

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHODS: Dispose of in accordance with local, state and federal regulations.

14. TRANSPORTATION INFORMATION

DOT STATUS: Not Regulated
PROPER SHIPPING NAME: N/D
HAZARD CLASS: N/D
UN NUMBER: N/D
PACKING GROUP: N/D
REPORTABLE QUANTITY: N/D

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

14. TRANSPORTATION INFORMATION, continued

IATA/ICAO STATUS: Not Regulated
PROPER SHIPPING NAME: N/D
HAZARD CLASS: N/D
UN NUMBER: N/D
PACKING GROUP: N/D
REPORTABLE QUANTITY: N/D

IMO STATUS: Not Regulated
PROPER SHIPPING NAME: N/D
HAZARD CLASS: N/D
UN NUMBER: N/D
PACKING GROUP: N/D
REPORTABLE QUANTITY: N/D
FLASH POINT: Non-flammable

15. REGULATORY INFORMATION

TSCA STATUS: N/A

CERCLA STATUS: N/A

SARA STATUS: N/A

RCRA STATUS: N/A

PROP 65 (CA): N/A

Neo-Synephrine Hydrochloride

ISSUED 08/19/98

16. OTHER INFORMATION

LEGEND: N/A = Not Applicable

N/D = Not Determined

N/L = Not Listed

L = Listed

C = Ceiling

S = Short-term

(R) = Registered Trademark of Abbott Laboratories

(TM) = Registered Trademark of Abbott Laboratories

The information and recommendations contained herein are based upon tests believed to be reliable. However, Abbott Laboratories does not guarantee their accuracy or completeness nor shall any of this information constitute a warranty, whether expressed or implied, as to the safety of the goods, the merchantability of the goods, or the fitness of the goods for a particular purpose. Adjustment to conform with actual conditions of usage may be required. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages arising from the use of these data. No freedom from infringement of any patent, copyright or trademark is to be inferred.

APPROVED BY: DLF